Two Sigma Advisers’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-24,500
| Closed | -$311K | – | 2541 |
|
|
2024
Q3 | $311K | Sell |
24,500
-400
| -2% | -$5.08K | ﹤0.01% | 1894 |
|
|
2024
Q2 | $418K | Buy |
24,900
+6,100
| +32% | +$102K | ﹤0.01% | 1957 |
|
|
2024
Q1 | $282K | Buy |
18,800
+500
| +3% | +$7.5K | ﹤0.01% | 2093 |
|
|
2023
Q4 | $275K | Sell |
18,300
-600
| -3% | -$9K | ﹤0.01% | 2132 |
|
|
2023
Q3 | $265K | Buy |
+18,900
| New | +$265K | ﹤0.01% | 2018 |
|
|
2019
Q2 | – | Sell |
-8,800
| Closed | -$325K | – | 2444 |
|
|
2019
Q1 | $325K | Buy |
8,800
+1,800
| +26% | +$66.5K | ﹤0.01% | 1961 |
|
|
2018
Q4 | $301K | Sell |
7,000
-1,100
| -14% | -$47.3K | ﹤0.01% | 1984 |
|
|
2018
Q3 | $383K | Sell |
8,100
-2,100
| -21% | -$99.3K | ﹤0.01% | 1893 |
|
|
2018
Q2 | $508K | Buy |
+10,200
| New | +$508K | ﹤0.01% | 1911 |
|